Abstract
Aims: This meta-analysis was performed to evaluate the relationships of a common polymorphism (T309G, rs2279744 T>G) in the murine double minute 2 (MDM2) gene with susceptibility and prognosis of nonsmall cell lung cancer (NSCLC). Methods: The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before November 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) or hazard risk (HR) with their 95% confidence intervals (95% CI) were calculated. Seven clinical studies with a total 3732 NSCLC patients and 1472 healthy controls met the inclusion criteria. Results: The results of our meta-analysis suggested that MDM2 T309G polymorphism might be strongly correlated with an increased risk of NSCLC (G allele vs. T allele: OR=1.63, 95% CI: 1.42-1.89, p<0.001; TG+GG vs. TT: OR=1.54, 95% CI: 1.31-1.80, p<0.001; respectively). Furthermore, we observed significant associations of MDM2 T309G polymorphism with poor overall survival (TT vs. GT: HR=1.22, 95% CI: 101-1.43, p<0.001; TT vs. GG: HR=1.31, 95% CI: 1.04-1.59, p<0.001; TT vs. GT+GG: HR=1.44, 95% CI: 1.13-1.76, p<0.001; respectively) and progression-free survival (TT vs. GT+GG: HR=1.26, 95% CI: 0.82-1.69, p<0.001) of NSCLC patients. Conclusions: Our findings provide convincing evidence that the MDM2 T309G polymorphism may contribute to individual differences in NSCLC susceptibility and prognosis. Thus, the MDM2 T309G polymorphism may be a promising potential biomarker for NSCLC diagnosis and prognosis.
Get full access to this article
View all access options for this article.